Drugs / LY3200882
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03792139 | Jan → Feb 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02937272 | Nov 2016 → Feb 2020 overdue | cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04031872 | Jan 2020 | colorectal cancer | The Netherlands Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04158700 | Dec 2019 → May 2023 | cancer of unknown primary site | Eli Lilly and Company | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3200882 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03792139 ↗ |
| Action | Inhibit | “small molecule inhibitor, LY3200882” PMID 34548321 ↗ Sep 2021 |
| Modality | Small molecule | — CHEMBL4594432 ↗ |
| Route | Oral | “Administered orally.” NCT03792139 ↗ |
| Target | TGFBR1 | “inhibitor of transforming growth factor-β (TGFβ) receptor 1” NCT04158700 ↗ |